Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, MPN, Clinical Research, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Aim. The aim of the study was to characterize the hematological and clinical correlates of higher CALR VAF in a large population of CALR mut pts with primary (PMF) and PET-MF.
Patients and Methods. All patients with a confirmed WHO2016 and IWG-MRT diagnosis of PMF and PET-MF, respectively, available in our database, who were CALR mutated, were included. CALR mut was assayed by PCR amplification and capillary gel electrophoresis starting from peripheral blood granulocytes. The VAF was determined by automated interpolation of the area under the curve, and expressed as the mutant peak area divided by (mutant peak area + wild-type peak area). Mutation analysis of a panel of 40 myeloid neoplasm-associated genes was performed by NGS (Oncomine, ThermoFisher). The nonparametric Wilcoxon rank-sum test, Kaplan-Meier estimate of survival and log-rank test were used as appropriate.
Results. A total of 121 pts (42 prePMF, 34.7%; 36 overt PMF, 29.8%; 43 PET-MF, 35.5%) were considered. Overall, T1 was found in 87 pts (71.9%), of which 8 (6.6%) were T1-like; T2 in 34 pts (28-1%), of which 3 (2.5%) T2-like. The median CALR VAF was 51.4+10.4%. For the purposes of the analysis, we considered at Higher VAF (CALR-h) pts having a VAF of >95% confidence interval of the distribution in the population, ie a VAF >55%, compared to Lower VAF (CARL-l; <55%). CALR-h was found in 28 pts, accounting for 23.1% of the study population. The frequency of T1 and T2 variants was similar in CALR-h and CALR-l pts, 71% and 28% and 71% and 29%, respectively. There was a significant trend of increased representation of CALR-h pts from prePMF (n=6, 14.3%) to overt PMF (n=8, 22.2%) and PET-MF (n=14, 32.6%); no difference in T1 and T2 relative representation in the different diagnostic category. ASXL1 mut were enriched among CALR-h pts (13/28, 46.4% vs CALR-l, 24/87, 27.6%; P=0.04) as it was the presence of any >1 mutation in an NGS-panel of myeloid genes (CALR-h 82.5% vs 57.5% in CALR-l, P=0.02). However, limited to HMR mutations, no difference was outlined. There was no significant difference between CALR-h and CALR-l pts as regards gender, age, IPSS score, karyotype abnormalities, BM fibrosis grade, constitutional symptoms, splenomegaly, thrombosis and bleeding events at diagnosis. On the other hand, CALR-h pts had lower Hb level (10.8 g/dl (8.3-14.6) vs 12.1 (7.4-16); P=0.02) and platelet count (466x109/L (102-1053) vs 661 (57-1800; P=0.02), and higher peripheral blood CD34+ cell counts (62.2x106/L (4-3450) vs 16.9 (0-2100); P=0.01). A greater proportion of CALR-h pts developed anemia during the FU (median 5.5y, range 0.3-33y). KM analysis revealed an anemia-free survival (Hb <10g/dL) of 7.9y (5.7-10y) in CALR-h vs 22.1y (13.9-30.3y) in CALR-l pts, P=0.004 (Figure). The HR (95%CI) was 3.1 (1.4-7.0). Also leukocytosis-free survival (leukocytes >25x109/L) was shorter in CALR-h pts (P=0.04), HR 2.55 (1.0-6.6). A CALR-h status did not impact on overall survival nor leukemia-free survival even after stratification based on disease subtype.
Discussion. We found that about 20% of CALR mut MF pts harbor a higher VAF, here defined as VAF >55%, that is associated with a more anemic phenotype at diagnosis and greater risk of developing anemia in the FU; however, in spite of anemia development, overall survival was not significantly impacted in the different disease categories. Whether a CALR-h condition has different impact in ET remains to be assessed in a separate study.
Disclosures: Guglielmelli: Novartis, Abbvie: Other: Other member of advisory board, speaker at meeting. Coltro: Novartis: Speakers Bureau. Szuber: Novartis: Honoraria. Vannucchi: Geron: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Morphosys: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Blueprint: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.
See more of: Oral and Poster Abstracts